Chronic Idiopathic Constipation Market – Synopsis
simple terms, constipation can be defined as the reduced stool frequency which could be less than three times per week. It can also be said to have difficulty passing stool. Chronic idiopathic constipation is a health condition in which the patient suffers from chronic symptoms of constipation. Moreover, constipation is one of the most frequently occurring Gastrointestinal (GI) complaints or problem.
Receive a Sample Report @ https://www.marketresearchfuture.com/sample_request/5931 .
According to a report by the World Gastroenterology Organization, 35 to 40 % of the world’s total population is suffering from acute or chronic GI complication. The increasing number of patients having GI diseases and disorders due to change in dietary pattern is the major factor for driving the global chronic idiopathic constipation market. According to reports from, Allergan and Ironwood Pharmaceuticals, Inc. major symptoms of constipation are infrequent stools (having a bowel movement less than three times a week), difficulty passing stools, which includes straining to have a bowel movement, not completely emptying bowels after a movement, hard or lumpy stools, gas pain, abdominal discomfort, and others.
On the other hand, low awareness regarding diagnosis and treatment methods for chronic idiopathic constipation may hamper the market growth during the forecast period.
Global Chronic Idiopathic Constipation market is expected to grow at a CAGR of 7.4% during the forecast period.
Key Players in the Global Chronic Idiopathic Constipation Market:
Some of the key players in this market are Actavis (U.S.), Chugai Pharmaceutical (Japan), Ferring International Center S.A.(Switzerland), Synergy Pharmaceuticals (U.S.), Pfizer Inc (U.S.), GlaxoSmithKline (U.K.), Sanofi (France), Bayer (Germany), Salix Pharmaceuticals Ltd (U.S.), Sucampo Pharmaceuticals Inc (U.S.), Ironwood Pharmaceuticals (U.S.), Progenics Pharmaceuticals (U.S.), F. Hoffmann-La Roche AG (Switzerland), Boehringer Ingelheim GmbH (Germany), Daewoong Co. Ltd.(South Korea), Synergy Pharmaceuticals, Inc. (U.S.) and others.
- The global chronic idiopathic constipation market is segmented on the basis of diagnosis, treatment, and end-user.
- On the basis of diagnosis, the market is segmented into blood tests, sigmoidoscopy, colonoscopy, balloon expulsion test, anorectal manometry, colonic transit study, defecography, and others.
- On the basis of treatment, the market is segmented into drug and surgery. Drugs are further segmented into acid neutralizers, laxatives and antidiarrheal, antiemetics, antiulcer, lubiprostone (amitiza) and linaclotide (linzess), misoprostol (Cytotec), colchicine/probenecid (Col-Probenecid) and Onabotulinumtoxin A (also called botulinum toxin type A or Botox), and others.
- On the basis of end-user, the market is segmented into hospitals, gastroenterology clinics, diagnostic centers and others.
The American chronic idiopathic constipation market is segmented into two regions, namely, North America and South America. North America, being the largest market, is mainly driven due to the increasing prevalence of chronic constipation and growing investment in healthcare. Furthermore, the U.S. is the largest market in North America owing to the presence of a large number of market players manufacturing medications for constipation. Canada is expected to be the fastest growing market which is driven by the overall increasing demand for diagnostic and treatment methods. South America is expected to be the fastest growing market due to technological advancements for diagnosis and increasing demand for treatment options of GI diseases.
The European chronic idiopathic constipation market exhibits growth with an increasing emphasis on the diagnosis and treatment of GI diseases and others. Moreover, Germany and the U.K. are the major contributors to the growth of the market. Additionally, the increasing expenditure in healthcare by major countries in Europe also accelerates the growth of the market.
Asia Pacific is expected to be the fastest growing market whose growth is attributed to a huge demand for diagnostic tests and increasing focus on early diagnosis and treatment of GI diseases. Furthermore, other factors contributing to the growth of the market are lifestyle changes, the influence of western culture among adults, and addiction to smoking.
On the other hand, the Middle East and Africa holds the least share of the market owing to the less availability of funds, limited availability of medical facilities, and poor political conditions in Africa. The Middle Eastern region holds the major share of the market owing to a well-developed technology and high healthcare expenditure. On the other hand, the African region shows the fastest growth due to the availability of opportunities for the market growth.
Access Report Details @ https://www.marketresearchfuture.com/reports/chronic-idiopathic-constipation-market-5931 .
TOC of Chronic Idiopathic Constipation Market:
1. Report Prologue
2. Market Introduction
2.2 Scope of The Study
2.2.1 Research Objective
3. Research Methodology
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
4. Market Dynamics
4.5 Macroeconomic Indicators
4.6 Technology Trends & Assessment
5. Market Factor Analysis
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Company Name: Market Research Future
Contact Person: Abhishek Sawant
Email: Send Email
Phone: +1 646 845 9312
Address:Market Research Future Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar